Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?

被引:17
作者
Campbell, Duncan J. [1 ,2 ]
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
关键词
amino-terminal pro-BNP (NT-proBNP); atrial fibrillation; B-type natriuretic peptide (BNP); cardiovascular disease; heart failure; myocardial infarction; risk factor; stroke;
D O I
10.1111/j.1440-1681.2008.04894.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The measurement of plasma levels of B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-proBNP) provides useful diagnostic information in patients with suspected heart failure and valuable prognostic information in patients with heart failure, acute coronary syndrome, valvular heart disease and other cardiac pathologies. 2. BNP- and NT-proBNP-guided heart failure therapy improves patient outcomes. 3. An increasing number of studies shows plasma BNP and NT-proBNP levels predict all-cause mortality and cardiovascular events including heart failure, myocardial infarction, stroke, atrial fibrillation and cardiovascular death in stable patients with or without known cardiovascular disease and provide information about cardiovascular risk additional to that provided by traditional risk factors. 4. Anti hypertensive therapy reduces elevated NT-proBNP levels in individuals at increased cardiovascular risk, thereby suggesting that change in NT-proBNP levels provides a measure of risk reduction. 5. Thus, monitoring of BNP and NT-proBNP levels offers the possibilities of improved targeting of individuals with increased cardiovascular risk and optimization of strategies for primary and secondary prevention of cardiovascular disease. 6. There is need for an outcome study to determine whether BNP- or NT-proBNP-guided therapy improves cardiovascular disease prevention.
引用
收藏
页码:442 / 446
页数:5
相关论文
共 59 条
[1]  
*AIHW, 2004, CARD DIS SER AIHW, V22
[2]   Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance [J].
Anan, F ;
Takahashi, N ;
Ooie, T ;
Hara, M ;
Yoshimatsu, H ;
Saikawa, T .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (06) :777-781
[3]   Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension [J].
Anan, F ;
Takahashi, N ;
Ooie, T ;
Yufu, K ;
Hara, M ;
Nakagawa, M ;
Yonemochi, H ;
Saikawa, T ;
Yoshimatsu, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (5-6) :353-359
[4]   Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study [J].
Aurigemma, GP ;
Gottdiener, JS ;
Shemanski, L ;
Gardin, J ;
Kitzman, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (04) :1042-1048
[5]   Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults - The strong heart study [J].
Bella, JN ;
Palmieri, V ;
Roman, MJ ;
Liu, JE ;
Welty, TK ;
Lee, ET ;
Fabsitz, RR ;
Howard, BV ;
Devereux, RB .
CIRCULATION, 2002, 105 (16) :1928-1933
[6]   N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease [J].
Bibbins-Domingo, Kirsten ;
Gupta, Reena ;
Na, Beeya ;
Wu, Alan H. B. ;
Schiller, Nelson B. ;
Whooley, Mary A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02) :169-176
[7]   Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study [J].
Blankenberg, Stefan ;
McQueen, Matthew J. ;
Smieja, Marek ;
Pogue, Janice ;
Balion, Cynthia ;
Lonn, Eva ;
Rupprecht, Hans J. ;
Bickel, Christoph ;
Tiret, Laurence ;
Cambien, Francois ;
Gerstein, Hertzel ;
Muenzel, Thomas ;
Yusuf, Salim .
CIRCULATION, 2006, 114 (03) :201-208
[8]   Soluble vascular cell adhesion molecule 1 and N-terminal Pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease [J].
Campbell, DJ ;
Woodward, M ;
Chalmers, JP ;
Colman, SA ;
Jenkins, AJ ;
Kemp, BE ;
Neal, BC ;
Patel, A ;
MacMahon, SW .
ARCHIVES OF NEUROLOGY, 2006, 63 (01) :60-65
[9]   Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease [J].
Campbell, DJ ;
Woodward, M ;
Chalmers, JP ;
Colman, SA ;
Jenkins, AJ ;
Kemp, BE ;
Neal, BC ;
Patel, A ;
MacMahon, SW .
HYPERTENSION, 2005, 45 (01) :69-74
[10]   Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease [J].
Campbell, DJ ;
Woodward, M ;
Chalmers, JP ;
Colman, SA ;
Jenkins, AJ ;
Kemp, BE ;
Neal, BC ;
Patel, A ;
MacMahon, SW .
CIRCULATION, 2005, 112 (01) :110-116